Aurobindo Pharma is currently trading at Rs. 605.00, up by 7.60 points or 1.27% from its previous closing of Rs. 597.40 on the BSE.
The scrip opened at Rs. 603.10 and has touched a high and low of Rs. 621.70 and Rs. 599.60 respectively. So far 211876 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.
Last one week high and low of the scrip stood at Rs. 621.70 and Rs. 582.35 respectively. The current market cap of the company is Rs. 35447.89 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.
Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.